Herbal Medicine Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, Malaysia.
PLoS One. 2021 Jan 19;16(1):e0245471. doi: 10.1371/journal.pone.0245471. eCollection 2021.
Hemp (Cannabis sativa subsp. sativa), commonly used for industrial purposes, is now being consumed by the public for various health promoting effects. As popularity of hemp research and claims of beneficial effects rises, a systematic collection of current scientific evidence on hemp's health effects and pharmacological properties is needed to guide future research, clinical, and policy decision making.
To provide an overview and identify the present landscape of hemp research topics, trends, and gaps.
A systematic search and analysis strategy according to the preferred reporting items for systematic review and meta-analysis-ScR (PRISMA-ScR) checklist on electronic databases including MEDLINE, OVID (OVFT, APC Journal Club, EBM Reviews), Cochrane Library Central and Clinicaltrials.gov was conducted to include and analyse hemp research articles from 2009 to 2019.
65 primary articles (18 clinical, 47 pre-clinical) were reviewed. Several randomised controlled trials showed hempseed pills (in Traditional Chinese Medicine formulation MaZiRenWan) improving spontaneous bowel movement in functional constipation. There was also evidence suggesting benefits in cannabis dependence, epilepsy, and anxiety disorders. Pre-clinically, hemp derivatives showed potential anti-oxidative, anti-hypertensive, anti-inflammatory, anti-diabetic, anti-neuroinflammatory, anti-arthritic, anti-acne, and anti-microbial activities. Renal protective effects and estrogenic properties were also exhibited in vitro.
Current evidence on hemp-specific interventions are still preliminary, with limited high quality clinical evidence for any specific therapeutic indication. This is mainly due to the wide variation in test item formulation, as the multiple variants of this plant differ in their phytochemical and bioactive compounds. Future empirical research should focus on standardising the hemp plant for pharmaceutical use, and uniformity in experimental designs to strengthen the premise of using hemp in medicine.
大麻(Cannabis sativa subsp. sativa)通常用于工业用途,现在正被公众用于各种促进健康的目的。随着大麻研究的普及和有益效果的宣称,需要系统地收集当前大麻对健康影响和药理特性的科学证据,以指导未来的研究、临床和政策决策。
提供大麻研究主题、趋势和差距的概述,并确定当前的研究领域。
根据系统评价和荟萃分析的首选报告项目(PRISMA-ScR)检查表,对包括 MEDLINE、OVID(OVFT、APC 期刊俱乐部、EBM Reviews)、Cochrane 图书馆中央和 Clinicaltrials.gov 在内的电子数据库进行了系统搜索和分析策略,以纳入和分析 2009 年至 2019 年的大麻研究文章。
共审查了 65 篇原始文章(18 篇临床研究,47 篇临床前研究)。几项随机对照试验表明,大麻籽丸(中药配方麻仁丸)改善功能性便秘的自发性肠蠕动。还有证据表明大麻依赖、癫痫和焦虑障碍有获益。临床前研究表明,大麻衍生物具有潜在的抗氧化、抗高血压、抗炎、抗糖尿病、抗神经炎症、抗关节炎、抗痤疮和抗菌活性。体外还显示出肾保护作用和雌激素特性。
目前关于大麻特异性干预的证据仍然初步,任何特定治疗适应症的高质量临床证据有限。这主要是由于测试项目配方的广泛变化,因为这种植物的多个变种在其植物化学和生物活性化合物方面存在差异。未来的实证研究应集中在大麻的药用标准化和实验设计的一致性上,以加强使用大麻作为药物的前提。